Allogeneic Stem Cell Transplantation

  • Richard F. AmbinderEmail author
  • Jennifer A. Kanakry
  • Christine Durand


Allogeneic bone marrow transplantation has emerged as an appropriate treatment for patients with HIV infection and standard indications for allogeneic bone marrow transplantation. The early experience before combination antiretroviral therapy and modern supportive measures was disappointing. However, in recent years, many successful transplants have been reported. In one case, HIV cure has been reported (in a patient with an HIV-resistant donor). In other patients maintained on antiretroviral therapy throughout the peritransplant period, substantial decreases in the long-term HIV reservoir have been documented. An interdisciplinary management team and attention to the details of the antiretroviral regimen used are important considerations. Regimens that avoid ritonavir-boosted protease inhibitors will minimize drug-drug interactions. The injectable antiretroviral enfuvirtide can be used to temporarily maintain antiretroviral coverage during periods of mucositis, nausea, or vomiting that may interfere with oral antiretroviral therapy. Symptomatic HIV rebound is a concern for patients whose antiretroviral therapy is interrupted after allogeneic bone marrow transplantation. This may in part reflect the naïveté of the donor immune system with regard to HIV. Therefore, patients whose therapy is interrupted should be monitored especially closely.


Aplastic Anemia Hodgkin Lymphoma Primary Central Nervous System Lymphoma Allogeneic Bone Marrow Transplantation Central Nervous System Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, Schneider T. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood. 2011;117(10):2791–9. doi: 10.1182/blood-2010-09-309591.CrossRefPubMedGoogle Scholar
  2. 2.
    Cooper C, Kanters S, Klein M, Chaudhury P, Marotta P, Wong P, Kneteman N, Mills EJ. Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS. 2011;25(6):777–86. doi: 10.1097/QAD.0b013e328344febb.CrossRefPubMedGoogle Scholar
  3. 3.
    Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28(15):2313–8. doi: 10.1097/QAD.0000000000000428.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Gupta V, Tomblyn M, Pedersen TL, Atkins HL, Battiwalla M, Gress RE, Pollack MS, Storek J, Thompson JC, Tiberghien P, Young JA, Ribaud P, Horowitz MM, Keating A. Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2009;15(7):864–71. doi: 10.1016/j.bbmt.2009.03.023.CrossRefGoogle Scholar
  5. 5.
    Hamadani M, Devine SM. Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. Blood. 2009;114(12):2564–6. doi: 10.1182/blood-2009-06-229666.CrossRefPubMedGoogle Scholar
  6. 6.
    Henrich TJ, Gandhi RT. Early treatment and HIV-1 reservoirs: a stitch in time? J Infect Dis. 2013. doi: 10.1093/infdis/jit307.Google Scholar
  7. 7.
    Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, Robles YP, Davis BT, Li JZ, Heisey A, Hill AL, Busch MP, Armand P, Soiffer RJ, Altfeld M, Kuritzkes DR. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med. 2014. doi: 10.7326/M14-1027.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM, Gallien S, Lin NH, Giguel FF, Lavoie L, Ho VT, Armand P, Soiffer RJ, Sagar M, Lacasce AS, Kuritzkes DR. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis. 2013;207(11):1694–702. doi: 10.1093/infdis/jit086.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Holland HK, Saral R, Rossi JJ, Donnenberg AD, Burns WH, Beschorner WE, Farzadegan H, Jones RJ, Quinnan GV, Vogelsang GB, et al. Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma. Ann Intern Med. 1989;111(12):973–81.CrossRefPubMedGoogle Scholar
  10. 10.
    Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, Schneider T, Hofmann J, Kucherer C, Blau O, Blau IW, Hofmann WK, Thiel E. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692–8. doi: 10.1056/NEJMoa0802905.CrossRefPubMedGoogle Scholar
  11. 11.
    Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, Herndier B, Northfelt DW, Huang J, Tulpule A, Levine AM. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336(23):1641–8. doi: 10.1056/NEJM199706053362304.CrossRefPubMedGoogle Scholar
  12. 12.
    Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N, Falk PM, Rosenthal J, Alvarnas J, Forman SJ. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005;105(2):874–8. doi: 10.1182/blood-2004-04-1532.CrossRefPubMedGoogle Scholar
  13. 13.
    Muller E, Barday Z, Mendelson M, Kahn D. HIV-positive-to-HIV-positive kidney transplantation–results at 3 to 5 years. N Engl J Med. 2015;372(7):613–20. doi: 10.1056/NEJMoa1408896.CrossRefPubMedGoogle Scholar
  14. 14.
    Petz LD, Redei I, Bryson Y, Regan D, Kurtzberg J, Shpall E, Gutman J, Querol S, Clark P, Tonai R, Santos S, Bravo A, Spellman S, Gragert L, Rossi J, Li S, Li H, Senitzer D, Zaia J, Rosenthal J, Forman S, Chow R. Hematopoietic cell transplantation with cord blood for cure of HIV infections. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2013;19(3):393–7. doi: 10.1016/j.bbmt.2012.10.017.CrossRefGoogle Scholar
  15. 15.
    Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B, Straus D. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(8):2171–8.Google Scholar
  16. 16.
    Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, Spina M, Manuele R, Vaccher E, Mazzucato M, Abbruzzese L, Ferremi P, Carosi G, Tirelli U, Rossi G. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114(7):1306–13. doi: 10.1182/blood-2009-02-202762.CrossRefPubMedGoogle Scholar
  17. 17.
    Serrano D, Miralles P, Balsalobre P, Kwon M, Rodriguez-Macias G, Gayoso J, Anguita J, Buno I, Berenguer J, Diez-Martin JL. Graft-versus-tumor effect after allogeneic stem cell transplantation in HIV-positive patients with high-risk hematologic malignancies. AIDS Res Hum Retroviruses. 2013;29(10):1340–5. doi: 10.1089/AID.2013.0001.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Shiels MS, Engels EA. Increased risk of histologically defined cancer subtypes in human immunodeficiency virus-infected individuals: clues for possible immunosuppression-related or infectious etiology. Cancer. 2012;118(19):4869–76. doi: 10.1002/cncr.27454.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Von Roenn J, Dezube BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008–16. doi: 10.1182/blood-2009-08-231613.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2008;14(1):59–66. doi: 10.1016/j.bbmt.2007.03.014.CrossRefGoogle Scholar
  21. 21.
    Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, Davis C, Blumberg E, Simon D, Subramanian A, Millis JM, Lyon GM, Brayman K, Slakey D, Shapiro R, Melancon J, Jacobson JM, Stosor V, Olson JL, Stablein DM, Roland ME. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363(21):2004–14. doi: 10.1056/NEJMoa1001197.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Woolfrey AE, Malhotra U, Harrington RD, McNevin J, Manley TJ, Riddell SR, Coombs RW, Appelbaum FR, Corey L, Storb R. Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation. Blood. 2008;112(8):3484–7. doi: 10.1182/blood-2008-05-157511.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Richard F. Ambinder
    • 1
    Email author
  • Jennifer A. Kanakry
    • 2
  • Christine Durand
    • 3
  1. 1.Department of OncologyJohns Hopkins School of MedicineBaltimoreUSA
  2. 2.National Institutes of HealthBethesdaUSA
  3. 3.Department of MedicineJohns Hopkins School of MedicineBaltimoreUSA

Personalised recommendations